

Blood Based Biomarkers Market - 2026-2035

<https://marketpublishers.com/r/B3A072008C9CEN.html>

Date: July 2026

Pages: 48

Price: US\$ 3,400.00 (Single User License)

ID: B3A072008C9CEN

Abstracts

Blood Based Biomarkers Market reached US\$ 10.78 billion in 2025 and is expected to reach US\$ 41.43 billion by 2035, growing with a CAGR of 14.20% during the forecast period 2026-2035.

The Blood Based Biomarkers Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Blood Based Biomarkers Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Biomarker Type

Genomic Biomarkers*

Proteomic Biomarkers

Metabolomic Biomarkers

Epigenetic Biomarkers

Cell Free DNA

Circulating Tumor DNA

Circulating Tumor Cells

Multi Biomarker Panels

Others

By Disease Area

Oncology*

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Hematologic Cancer

Cardiovascular Diseases

Neurological Disorders

Infectious Diseases

Autoimmune Diseases

Metabolic Disorders

Prenatal Health

Others

By Application

Screening*

Diagnosis

Risk Stratification

Prognosis

Therapy Selection

Companion Diagnostics

Treatment Monitoring

Recurrence Monitoring

By Technology

PCR*

NGS

Targeted Sequencing

Whole Genome Sequencing

Whole Exome Sequencing

ELISA

Immunoassays

Mass Spectrometry

Proteomics Platforms

Others

By Sample Type

Plasma*

Serum

Whole Blood

By End User

Hospitals*

Diagnostic Laboratories

Cancer Centers

Pharma and Biotechnology Companies

CROs

Research Institute

Regional Analysis for Blood Based Biomarkers Market:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

Go-to-market Strategy.

Neutral perspective on the market performance.

Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

Customized regional/country reports as per request and country level analysis.

Potential & niche segments and regions exhibiting promising growth covered.

Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Blood Based Biomarkers Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Data
 - 1.1.1. Secondary Data
 - 1.1.2. Primary Data
 - 1.1.3. CAGR Analysis
- 1.2. Market Size Estimation Methodology
 - 1.2.1. Bottom-Up Approach
 - 1.2.2. Top-Down Approach
- 1.3. Market Breakdown & Data Triangulation
- 1.4. Research Assumptions
- 1.5. Limitations

2. DEFINITION AND OVERVIEW

- 2.1. Study Objectives
- 2.2. Market Definition
- 2.3. Market Scope
- 2.4. Stakeholder Analysis
- 2.5. Currency Considered
- 2.6. Study Period

3. EXECUTIVE SUMMARY

- 3.1. Key Takeaways
- 3.2. Top To Bottom Analysis
- 3.3. Market Share Analysis
- 3.4. Data Points from Key Primary Interviews
- 3.5. Data Points from Key Secondary Databases
- 3.6. Market Snapshot
- 3.7. Geographical Snapshot

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising Shift Toward Minimally Invasive Diagnostics

- 4.1.1.2. Growing Demand for Early Disease Detection
- 4.1.1.3. Expansion of Precision Medicine and Companion Diagnostics
- 4.1.2. Restraints
 - 4.1.2.1. Clinical Validation and Reimbursement Challenges
 - 4.1.2.2. High Cost of Advanced Biomarker Platforms
- 4.1.3. Impact Analysis - Drivers and Restraints
- 4.1.4. Opportunity
 - 4.1.4.1. Growth in Multi Cancer Early Detection Testing
 - 4.1.4.2. Emerging Use in Neurological Disorders
- 4.1.5. Trends
 - 4.1.5.1. AI Enabled Multi Biomarker Interpretation
 - 4.1.5.2. Shift From Single Biomarker Tests to Multi Biomarker Panels
- 4.1.6. Challenges
 - 4.1.6.1. Low Clinical Utility for Some Emerging Biomarkers
 - 4.1.6.2. Data Interpretation Complexity

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis

5.2. Political Factors

5.3. Social Factors

5.3.1. Rising patient preference for minimally invasive testing is increasing adoption of blood based biomarker diagnostics

5.3.2. Growing awareness of early disease detection is encouraging preventive screening for cancer, cardiovascular diseases and neurological disorders

5.3.3. Increasing acceptance of personalized medicine is supporting demand for biomarker guided diagnosis, therapy selection and treatment monitoring

5.4. Economic Factors

5.4.1. Rising healthcare spending on precision diagnostics is creating sustained demand for advanced blood based biomarker platforms

5.4.2. Growing investment by pharma and biotech companies in companion diagnostics is expanding commercial use of blood based biomarkers

5.4.3. Increasing cost burden of late stage disease treatment is pushing healthcare systems toward early detection and routine monitoring solutions

5.5. Geopolitical Factors

5.6. Supply/Value Chain Analysis

5.7. Pricing Analysis

5.8. Regulatory Analysis

5.9. Technology Landscape

- 5.10. Innovation & R&D Trends
- 5.11. Sustainability and ESG Analysis
- 5.12. Risk Avoidance Model
- 5.13. Go-To-Market (GTM) Strategy
- 5.14. BCG Matrix
- 5.15. Business Models Analysis
- 5.16. Demand-Supply Gap
- 5.17. Risk Mitigation Framework
- 5.18. Compliance Roadmap
- 5.19. Strategic Implications
- 5.20. Emerging Opportunities
- 5.21. Adoption Trends
- 5.22. Disruption Analysis
- 5.23. DMI Opinion

6. BY BIOMARKER TYPE

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
 - 6.1.2. Market Attractiveness Index, By Biomarker Type
- 6.2. Genomic Biomarkers*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Proteomic Biomarkers
- 6.4. Metabolomic Biomarkers
- 6.5. Epigenetic Biomarkers
- 6.6. Cell Free DNA
- 6.7. Circulating Tumor DNA
- 6.8. Circulating Tumor Cells
- 6.9. Multi Biomarker Panels
- 6.10. Others

7. BY DISEASE AREA

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
 - 7.1.2. Market Attractiveness Index, By Disease Area
- 7.2. Oncology*
 - 7.2.1. Introduction

- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Breast Cancer
- 7.2.4. Lung Cancer
- 7.2.5. Colorectal Cancer
- 7.2.6. Prostate Cancer
- 7.2.7. Hematologic Cancer
- 7.3. Cardiovascular Diseases
- 7.4. Neurological Disorders
- 7.5. Infectious Diseases
- 7.6. Autoimmune Diseases
- 7.7. Metabolic Disorders
- 7.8. Prenatal Health
- 7.9. Others

8. BY APPLICATION

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 8.1.2. Market Attractiveness Index, By Application
- 8.2. Screening*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Diagnosis
- 8.4. Risk Stratification
- 8.5. Prognosis
- 8.6. Therapy Selection
- 8.7. Companion Diagnostics
- 8.8. Treatment Monitoring
- 8.9. Recurrence Monitoring

9. BY TECHNOLOGY

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
 - 9.1.2. Market Attractiveness Index, By Technology
- 9.2. PCR*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. NGS

- 9.3.1. Targeted Sequencing
- 9.3.2. Whole Genome Sequencing
- 9.3.3. Whole Exome Sequencing
- 9.4. ELISA
- 9.5. Immunoassays
- 9.6. Mass Spectrometry
- 9.7. Proteomics Platforms
- 9.8. Others

10. BY SAMPLE TYPE

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
 - 10.1.2. Market Attractiveness Index, By Sample Type
- 10.2. Plasma*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Serum
- 10.4. Whole Blood

11. BY END USER

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.1.2. Market Attractiveness Index, By End User
- 11.2. Hospitals*
 - 11.2.1. Introduction
 - 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Diagnostic Laboratories
- 11.4. Cancer Centers
- 11.5. Pharma and Biotechnology Companies
- 11.6. CROs
- 11.7. Research Institute

12. BY REGION

- 12.1. Introduction
 - 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 12.1.2. Market Attractiveness Index, By Region

12.2. North America*

12.2.1. Introduction

12.2.2. Key Region-Specific Dynamics

12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area

12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type

12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

13. U.S.

13.1. Canada

13.1.1. Mexico

13.2. Europe

13.2.1. Introduction

13.2.2. Key Region-Specific Dynamics

13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area

13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type

13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

13.2.9.1. Germany

13.2.9.2. UK

13.2.9.3. France

13.2.9.4. Russia

13.2.9.5. Spain

13.2.9.6. Italy

13.2.9.7. Poland

13.2.9.8. Rest of Europe

13.3. Latin America

13.3.1. Introduction

13.3.2. Key Region-Specific Dynamics

13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area

13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 13.3.9.1. Brazil

- 13.3.9.2. Argentina

- 13.3.9.3. Rest of Latin America

13.4. Asia-Pacific

- 13.4.1. Introduction

- 13.4.2. Key Region-Specific Dynamics

- 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

- 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area

- 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

- 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

- 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type

- 13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

- 13.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 13.4.9.1. China

- 13.4.9.2. India

- 13.4.9.3. Japan

- 13.4.9.4. Australia

- 13.4.9.5. South Korea

- 13.4.9.6. Indonesia

- 13.4.9.7. Malaysia

- 13.4.9.8. Rest of Asia-Pacific

13.5. Middle East and Africa

- 13.5.1. Introduction

- 13.5.2. Key Region-Specific Dynamics

- 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

- 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area

- 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

- 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

- 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type

- 13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

- 13.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 13.5.9.1. UAE

- 13.5.9.2. Saudi Arabia

- 13.5.9.3. South Africa

- 13.5.9.4. Israel

13.5.9.5. Turkiye

13.5.9.6. Rest of Middle East and Africa

14. COMPETITIVE LANDSCAPE

14.1. Competitive Scenario

14.2. Market Share Analysis - Global

14.3. Market Share Analysis - North America

14.4. Market Share Analysis - Europe

14.5. Market Share Analysis - Asia-Pacific

14.6. Mergers and Acquisitions Analysis

14.7. Partner Identification Analysis

14.8. Investment & Funding Landscape

14.9. Strategic Alliances & Innovation Pipeline

15. COMPANY PROFILES

15.1. Guardant Health, Inc.*

15.1.1. Company Overview

15.1.2. Product Portfolio and Description

15.1.3. Revenue Analysis

15.1.4. Pricing Analysis

15.1.5. SWOT Analysis

15.1.6. Recent Developments

15.1.6.1. Major Deals

15.1.6.2. M&A

15.1.6.3. Collaboration

15.1.6.4. Acquisition

15.1.6.5. Joint Ventures

15.1.6.6. Innovations

15.1.7. Recent News

15.1.7.1. Events

15.1.7.2. Conferences

15.1.7.3. Symposiums

15.1.7.4. Webinars

16. GRAIL, INC.

16.1. Natera, Inc.

- 16.2. Foundation Medicine, Inc.
- 16.3. F. Hoffmann-La Roche Ltd
- 16.4. Thermo Fisher Scientific Inc.
- 16.5. QIAGEN
- 16.6. Abbott
- 16.7. Siemens Healthcare Private Limited
- 16.8. bioMérieux
- 16.9. Beckman Coulter, Inc
- 16.10. Illumina, Inc.
- 16.11. Bio-Rad Laboratories, Inc.
- 16.12. Sysmex Europe SE.
- 16.13. Freenome Holdings, Inc.
- 16.14. Labcorp
- 16.15. Quest Diagnostics Incorporated.
- 16.16. Exact Sciences Corporation.
- 16.17. Tempus
- 16.18. Personalis, Inc. (LIST NOT EXHAUSTIVE)

17. APPENDIX

- 17.1. About Us and Services
- 17.2. Contact Us

I would like to order

Product name: Blood Based Biomarkers Market - 2026-2035

Product link: <https://marketpublishers.com/r/B3A072008C9CEN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B3A072008C9CEN.html>